Company news
Mindset Pharma Inc news in 2021
Mindset Pharma Inc's news releases, calls and decks from 2021, newest first.
Mindset Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
October 6, 2021
Mindset Announces Participation at Upcoming Events in June 2021
June 1, 2021
Mindset Pharma Invited to Present at Canaccord Genuity 41st Annual Growth Conference
May 5, 2021
Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds
April 29, 2021
Mindset Pharma Engages KCSA Strategic Communications to Provide Investor Relations Services
April 28, 2021
Mindset Pharma Invited to Present at H.C. Wainwright "Psychedelics in Psychiatry and Beyond" Virtual Conference
April 26, 2021
Mindset Pharma Announces Strong Confirmation of In Vivo Proof-of-Concept Across Its Entire New Drug Program Portfolio
April 20, 2021
Mindset Pharma Announces Exercise of Over-Allotment Option for Additional Gross Proceeds of $1.052 Million
April 19, 2021
Mindset Pharma Announces Closing of $7.5 Million Bought Deal Public Offering
April 15, 2021
Mindset Pharma Announces Filing of Amended and Restated FS and MD&A for the Three and Six Month Period Ended December 31, 2020
April 1, 2021
Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development
March 30, 2021
Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("Cope"); Cope Expected to Be World's First in Vivo Psychedelic Benchmark Data Set
March 23, 2021
Mindset Pharma Announces Upsize of Bought Deal to $7.5 Million
March 22, 2021
Mindset Pharma Announces $5 Million Bought Deal Financing
March 22, 2021
Mindset Pharma Announces DTC Eligibility for OTCQB(R) Venture Listing
March 17, 2021
Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its Psychedelic Drug Candidates Pipeline With Novel DMT & 5-MeO-DMT Analogs
March 15, 2021
Mindset Pharma to Present at the Stifel GMP Conference - Psychedelics: Addressing the Global Mental Health Crisis
March 10, 2021
Mindset Pharma Appoints Leading Molecular Pharmacologist & Formulation Expert Dr. Joseph Gabriele to Scientific Advisory Board
March 8, 2021
Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process
February 22, 2021
Mindset Pharma Added to North American Psychedelics Index
February 19, 2021
Mindset Pharma Announces U.S. Listing Application for OTCQB Venture Market
February 17, 2021
Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates
February 10, 2021
Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds
February 5, 2021
Mindset Pharma Retains Corporate Development Advisors
February 1, 2021
Mindset Selects Compounds from Its Third Psilocybin-Inspired Drug Family to Move into in vivo PoC Studies
February 1, 2021
Mindset Pharma Announces Listing on the Frankfurt Stock Exchange
January 27, 2021
Mindset Pharma to Present at Inaugural KCSA Psychedelic Investor Conference
January 20, 2021
Mindset Pharma Invited to Present at Upcoming Canaccord Genuity Mental Health Conference
January 14, 2021
Mindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of Potential Clinical Use Cases Including Micro-Dosing
January 6, 2021